Abstract -In order to study the function of the Ankrd2 protein, for which commercial antibodies are not available, we report the production and analysis of polyclonal antibodies to full-length Ankrd2 and its C-terminal and N-terminal regions, as well as a monoclonal antibody to the C-terminus of the protein� Epitope mapping making use of recombinant deletion mutants showed that an epitope located in region 323-333 aa of Ankrd2 is detected by the monoclonal antibody� The high specificity of all four anti-Ankrd2 antibodies for recombinant and endogenous Ankrd2 protein is also demonstrated�
INTRODUCTION
Three closely related proteins -CARP (cardiac ankyrin repeat protein; Ankrd1 or MARP1), Ankrd2 (ankyrin repeat domain 2; Arpp or MARP2), and DARP (diabetes-related ankyrin repeat protein; MARP3) -have been allocated to the muscle ankyrin repeat protein (MARP) family (Miller et al�, 2��3)� Miller et al�, 2��3)� Muscle ankyrin repeat proteins are characteri�ed by ankyrin repeat proteins are characteri�ed by are characteri�ed by modular structure, muscle-specific expression, and dual cellular locali�ation (nuclear and cytoplasmic)� They can play important structural and signalling roles and link the elastic I-band region as a passive stretch sensor to the control of transcription� Kemp et al� (2���) identified Ankrd2 as a novel identified Ankrd2 as a novel Ankrd2 as a novel as a novel transcript expressed in fast tibialis anterior muscles after 7 days of passive stretch immobili�ation in vivo� In addition to this, Ankrd2 was also dis-discovered through systematic sequencing of human skeletal muscle 3´-expressed sequence tags (ESTs) (�anfranchi et al�, 1���) , showing �3�� identity at �anfranchi et al�, 1���), showing �3�� identity at ), showing �3�� identity at the amino acid level to CARP, a nuclear protein expressed in heart (Zou et al�, 1��7), endothelial cells (Chu et al�, 1��5) and (to a lesser extent) in skeletal muscle (Baumeister et al�, 1��7)� The human Ankrd2 gene encodes a 37-kDa protein that has a nuclear locali�ation signal (N�S), two PEST protein-destabili�ation motifs, and four ankyrin-repeat domains (Kemp et al�, 2���; Moriyama et al�, 2��1; Pallavicini et al�, 2��1)� Ankyrin repeats are ubiquitous motifs involved in macromolecular interactions, whereas PEST sequences (rich in Pro, Glu, Asp, Ser, and Thr) serve as signals that target proteins for rapid destruction� Although Ankrd2 is predominantly expressed in skeletal muscle, in the I band of the sarcomere (Tsukamoto et al�, 2��2) , it is also found in adult heart (Pallavicini et al�, 2��1; Ishiguro et al�, 2��2)� It becomes strongly upreguIt becomes strongly upregulated in myocytes upon stretch (Kemp et al�, 2���) , with denervation of skeletal muscle (Tsukamoto et al�, 2��2) , and during eccentric exercise (Barash et al�, 2���), suggesting its role in muscle cell response to acute stress� It has been shown that Ankrd2 can interact with the Z-disk proteins titin (Miller et al�, 2��3) and telethonin (Kojic et al�, 2���), as well as with three transcription factors: YB1, PM�, and p53 (Kojic et al�, 2���)� The observation that Ankrd2 can interact with proteins located both in the nucleus and in the Z-disk supports the hypothesis of its potential role as a molecular messenger shuttling between the nucleus and the cytoplasm� Not only does Ankrd2 bind p53, both in vitro and in vivo, it also enhances upregulation of the p21 WAFI/CIPI promoter by p53 (Kojic et al�, 2���)� These findings suggest that Ankrd2 may be involved in sensing stress signals and linking these to muscle gene regulation� In this paper, we describe a preparation of four anti-Ankrd2 antibodies (three polyclonal and one monoclonal) and precise mapping of their epitopes in order to define their specificity for the Ankrd2 protein� In view of the dual locali�ation of Ankrd2 in muscle cells and the presence of a common motif such as ankyrin repeats, it is important to determine that anti-Ankrd2 antibodies specifically recogni�e the Ankrd2 protein and no other protein containing ankyrin repeats in muscle and heart tissue�
MATERIA�S AND METhODS

Constructs
Full-length (F�-Ankrd2, 13-��� bp) and C1-Ankrd2 (721-��� bp) cDNAs were amplified by PCR, while N1-Ankrd2 (13-51� bp) cDNA was generated by restriction digestion (KpnI and hindIII) of fulllength Ankrd2 cDNA� All three cDNAs were inserted into the pQE3� expression vector (Qiagen) in frame with the �-histidine tag� Further, F�-Ankrd2 (13-��� bp), N-Ankrd2 (13-3�� bp), NA-Ankrd2 (13-852bp), C-Ankrd2 (83�-��� bp), AC-Ankrd2 (3�1-��� bp), DC-Ankrd2 (13-��� bp), UC-Ankrd2 (13-��8 bp), and SC-Ankrd2 (���-��� bp) cDNAs were amplified by PCR and cloned into the pGEX-�P-3 vector (GE healthcare) in frame with the GST tag�
Expression and purification of His-tagged recombinant proteins
his-tagged recombinant proteins were produced using the QIAexpress system (QIAGEN)� The Ankrd2 constructs in pQE3� were transformed in E. coli strain M15 carrying pREP�� Bacteria were grown in �B containing 1�� μg/ml ampicillin and 3� μg/ml kanamycin� Expression from the pQE3� vector was induced by adding isopropyl-β-D-thi- 
Polyclonal antibody production
his-tagged recombinant proteins, purified under denaturing conditions, were used for immuni�ation of BA�B/c mice� Prior to the first injection, blood was taken from the carotid artery; pre-immune sera were prepared and tested by Western blot in order to check for any reactivity against muscle proteins�
Mice were immuni�ed with �� μg of purified proteins [diluted in PBS and mixed with Freund's incomplete adjuvant (SIGMA)] by intra-peritoneal injection� Every three weeks mice were injected with proteins� After three injections, a blood sample was taken; thereafter boosts were given every three weeks and samples taken once every three weeks� Sera were prepared by allowing the blood to coagulate (37°C for 3� min) and then centrifuging at 12���g at �°C for 3� min� To avoid the growth of bacteria and fungi, sodium a�ide was added to the sera to a final concentration of ���2��� Samples were aliquoted and stored at -2�°C� All collected sera were tested by Western blot analysis for immunoreactivity against human striated muscle proteins�
Monoclonal antibody production
A modified version of the protocol of harlow and �ane (harlow and �ane, 1��8) was used for production of monoclonal antibodies� here BA�B/c female mice were immuni�ed as already described for the production of polyclonal antibodies� When a good immune response was obtained, the animals were sacrificed� The spleen was taken and the cells disso-ciated and then fused with NP1 myeloma cells in the presence of polyethylene glycol� After fusion, hybridoma cells were selected using RPMI medium supplemented with sodium hypoxanthine aminopterin and thymidine (hAT, SIGMA)� Clones were tested by en�yme-linked-immunosorbent assay (E�ISA) en�yme-linked-immunosorbent assay (E�ISA) (E�ISA) against the Ankrd2 protein� In order to obtain monoclonal cell lines, positive clones were subcloned, tested by E�ISA, and then grown in DMEM supplemented with hAT� These monoclonal cell lines were tested by Western blot analysis for immunoreactivity against striated muscle proteins�
Expression and purification of GST-tagged recombinant proteins
Production of GST-tagged recombinant proteins and their purification were accomplished using the Glutathione-S-transferase Gene Fusion System (GE healthcare)� The Ankrd2 constructs in pGEX-�P-3 expression vector were transformed in E. coli strain B�21(DE3)-p�ys S (Promega) and grown in �B with ampicillin (1�� μg/ml)� The GST-recombinant protein expression was induced by adding IPTG to a final concentration of ��5-1 mM and the bacteria were grown for an additional 3 h at room temperature� Cells were pelleted by centrifugation, resuspended in lysis buffer [5� mM Tris-hCl, ph 8, 5�� glycerol, 1�� Triton X-1��, 2 mM DTT, and a cocktail of protease inhibitors (Complete Mini, EDTA-free, Roche)], and sonicated� Debris from the cell ly�ate was removed by centrifugation and the supernatant was incubated with Glutathione Sepharose-�C�B beads (GE healthcare) for 1 h at �°C� After removal of non-specifically bound proteins by washing resins with PBS [8� mM Na 2 hPO � , 2� mM Nah 2 PO � , 1�� mM NaCl, and a cocktail of protease inhibitors (Complete Mini, EDTA-free, Roche)], the GST-recombinant proteins were eluted from the beads with 2� mM glutathione dissolved in 5� mM Tris-hCl, ph 8� Quality and quantity of the purified proteins were evaluated by SDS-PAGE followed by Coomassie Brilliant Blue staining�
Western blot analysis
Recombinant GST-tagged proteins or human heart (human heart Protein Medlay, Clontech) and skeletal muscle proteins (human Skeletal Muscle Protein Medley, Clontech) were separated by SDS-PAGE and blotted onto PVDF membrane (Immobilon P, Millipore)� The membrane was incubated in blocking solution [1��� non-fat dried milk in PBS-T (8� mM Na 2 hPO � , 2� mM Nah 2 PO � , 1�� mM NaCl, �,1�� (v/v) Tween 2�, ph 7�5)] at �°C overnight, followed by 1-h incubation with each of the primary or secondary antibodies diluted in 5�� non-fat dried milk in PBS-T� Detection of Ankrd2 was with mouse monoclonal antibody and mouse polyclonal antibodies to full length, the N-terminus, and the C-terminus of Ankrd2� All antibodies were diluted ��� times� Both alkaline phosphatase (AP)-and horseradish peroxidase (hRP)-conjugated secondary antibodies were used for protein visuali�ation, depending on the detection method employed: the NBT/BCIP colorimetric detection system (Promega, Milan, Italy) or the EC� detection reagent (Millipore, Milan, Italy)�
RESU�TS
Antigen and antibody preparation
In order to produce antibodies to the Ankrd2 protein, the full-length (5-333 aa) protein and two fragments of Ankrd2, N1-Ankrd2 (5-173 aa) and C1-Ankrd2 (2�1-333 aa), were used as antigens� Polyclonal antibodies were raised against the whole protein (anti-F�-Ankrd2), as well as the N-(anti-NAnkrd2) and C-terminal (anti-C-Ankrd2) regions of Ankrd2� Monoclonal antibody was prepared against the C-terminus of Ankrd2�
The antigens were expressed in E. coli as histagged recombinant proteins and used for immuni�ation of mice� Spleen cells isolated from mice immuni�ed with his-tagged C-terminal Ankrd2 were fused with NP1 myeloma cells and selected for hybridoma cells secreting Ankrd2 monoclonal antibody� Epitope mapping was performed for clone 2F1��
Mapping antigenic epitope for monoclonal anti-Ankrd2 antibody
Since the C-terminal region of Ankrd2 (2�1-333 aa) was used for the production of monoclonal antibod-ies, we wanted to check for a potential epitope� We searched for regions that might be able to adopt a conformation with exposed secondary structure, thereby representing potential antigen epitopes� The sequence of the Ankrd2 region from 2�1-333 aa was analy�ed using ProtScale software (www�expasy�ch) (Gasteiger, 2��5), which allows the computation and representation of the profile produced by any amino acid scale on a selected protein� The hydrophobicity scale was used here, and results of the prediction are presented in Fig� 1� Four regions (2�7-255 aa, 3�5-31� aa, 317-325 aa, and 32�-328 aa) with the lowest scores are designated, suggesting the most hydrophilic regions that could represent potential epitopes� The same regions were also predicted to be the most hydrophilic when the Ankrd2 sequence from amino acid 2�1-333 was analy�ed by ProtScale choosing the hydrophilicity scale (data not shown)� In order to precisely map the antigenic epitope for monoclonal anti-Ankrd2 antibody several constructs were made with the aim of defining the minimal region of the Ankrd2 protein recogni�ed by the anti-Ankrd2 monoclonal antibody� The following regions were selected: UC-Ankrd2 (5-31� aa), containing the first and second potential epitopes; DC-Ankrd2 (5-323 aa), containing the first, second, and third potential epitopes; SC-Ankrd2 (317-333 aa), containing third and fourth potential epitopes The monoclonal antibody raised against the C-terminus of Ankrd2 interacted only with recombinant proteins containing the last 1� aa of the Cterminus, vi��, C (27�-333 aa), AC (12�-333 aa), and SC (317-333 aa), but not with the Ankrd2 fragments UC (5-31� aa) and DC (5-323 aa) (Fig� 3, panel C)� As expected, the antibody to the full-length protein could detect the proteins expressed by the all of the GST-Ankrd2 constructs, but not GST alone (Fig� 3, panel B)� We therefore deduced that the monoclonal antibody (clone 2F1�) epitope maps the region between amino acids 323 to 333, at the very end of the Ankrd2 protein�
Determination of specificity of the polyclonal anti-N-terminal and anti-C-terminal Ankrd2 antibodies
Antigens used for production of anti-N-terminal (5-173 aa) and anti-C-terminal (2�1-333 aa) Ankrd2 antibodies contained some of the ankyrin repeats (12�-278 aa)� To exclude the possibility that polyclonal anti-N-terminal antibody recogni�es ankyrin repeats, we checked it against the same set of deletant mutants used to map the epitope of the monoclonal antibody, with the addition of an Ankrd2 fragment containing the N-terminal region of Ankrd2 (N, 5-12� aa, Fig� 2)� To test the polyclonal antibody raised against the C terminus of Ankrd2, we used an Ankrd2 fragment containing the N-terminus and ankyrin repeats (NA, 5-278 aa, Fig� 2), as well as the C-terminus (C, 27�-333 aa)� Purified GST recombinant proteins were subjected to SDS-PAGE, blotted, and the blots probed with polyclonal anti-N-Ankrd2 ( The C-terminal region of Ankrd2 with ankyrin repeats (AC) was not detected by the N-terminal polyclonal antibody (Fig� 3, panel D) , suggesting that this antibody is specific for the N-terminal region of Ankrd2 and does not cross react with the ankyrin repeats� Polyclonal antibody raised against the C-terminus of Ankrd2 reacted with the C-terminus of the Ankrd2 protein, but not with the N-terminus and ankyrin repeats (Fig� �), thus demonstrating that this antibody is also specific for the Ankrd2 protein�
Anti-Ankrd2 antibodies recognize endogenous Ankrd2 in human heart and skeletal muscle
The specificity of all anti-Ankrd2 antibodies was tested by Western blot analysis of human heart and skeletal muscle proteins� The proteins were separated by SDS-PAGE and blotted� Endogenous Ankrd2 was detected by all four anti-Ankrd2 antibodies� Figure 5 shows a single �3-kDa band corresponding to endogenous Ankrd2, detected in both human heart and skeletal muscle protein extracts� DISCUSSION For investigation of newly discovered proteins, ones for which commercial antibodies are not available, it is helpful to produce specific antibodies as an alternative to tags and tag-specific antibodies� here we present the production and analysis of three mouse polyclonal and one monoclonal antibody raised against the full-length protein, the N-terminus and, the C-terminus of the Ankrd2 protein� The choice of antigens was based on modular structure of the Ankrd2 protein, the N-terminus (1-12� aa), ankyrin repeats in the middle portion of the protein (121-278 aa), and the C-terminus (27�-333 aa)� Recombinant his-tagged proteins purified under denatured conditions were used for immuni�a-tion of mice� Although all anti-Ankrd2 antibodies were generated against denatured antigens, they recogni�ed denatured Ankrd2 in human heart and skeletal muscle extracts (Fig� 5), as well as native protein in muscle tissue (as demonstrated by immunohistochemistry) (Pallavicini et al�, 2��1)� We experimentally confirmed the theoretical prediction of potential epitopes represented by amino acid sequences that may adopt an exposed conformation based on ProtScale analysis of Ankrd2 C-terminus� Using a panel of deletant mutants, we precisely mapped the epitope specifically recogni�ed by the monoclonal anti-Ankrd2 antibody (clone 2F1�) to the region of the last 1� aa of Ankrd2 (323-333 aa)� This region may represent a linear epitope, to judge from its si�e� Epitope si�e is defined by the binding site of the antibody and limited by complementary binding between antigen and antibody� Epitopes can be linear or conformational� Typically, �-7 amino acids or sugars can fit into the deep pocket structures of linear epitope binding sites; for example, the � his tag is only six amino acids but can be seen by its specific antibody� On the other hand, conformational epitopes of globular proteins cover much greater space on flatter surface binding sites of antibody and may consist of 15-22 amino acids (Kindt et al�, 2���)� As the anti-N-and anti-C-Ankrd2 antibodies were made using the corresponding regions and a part of ankyrin repeats, we took into account the fact that the ankyrin repeats represent a common motif composed of 33 aa that mediate protein-protein interactions (Michaely and Bennett, 1��2)� We here confirm that the anti-N-terminal and anti-C-terminal Ankrd2 antibodies are specific for the N-and C-termini of Ankrd2 and do not recogni�e Ankrd2 ankyrin repeats; they are therefore unlikely to cross react with the large number of ankyrin repeat proteins in cells� Western blot analysis of human heart and skeletal muscle proteins showed the existence of a single band that corresponds to the endogenous Ankrd2 protein, thus demonstrating the specificity of these antibodies raised against the human striated muscle protein Ankrd2� It has already been seen that Ankrd2 is more abundantly expressed in skeletal muscle than in the adult heart (Moriyama et al�, 2��1), as shown in Fig� �� It would appear that the polyclonal anti-C-Ankrd2 antibody demonstrated the lowest affinity for endogenous Ankrd2�
In conclusion, we have characteri�ed a set of highly specific and defined antibodies produced in order to study a MARP protein family member, Ankrd2�
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